2 days ago
Apellis’ SYFOVRE® (pegcetacoplan) TGA Approved
Apellis Pharmaceuticals, Inc. announced today that Australia’s Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the treatment of adult patients with geographic atrophy (GA). It is the first and only approved treatment for GA in Australia.
Retina Australia welcomed this milestone decision offering hope to the over 75,000 Australians living with geographic atrophy (GA), a severe form of age-related macular degeneration (AMD). This treatment provides the first real opportunity to slow vision loss, helping to preserve both quality of life and independence for those affected.
For more information, please refer the Apellis press release here.
https://retinaaustralia.com.au/first-treatment-for-geographic-atrophy-approved-in-australia/
Other Blogs
Podcast: Dealing with inherited retinal disease
Talking Eyes with Lien Trinh Guest speaker: Professor Lauren Ayton Talking Eyes is an Australian podcast dedicated to exploring the latest...
World Research Summary by Dr Catherine Civil
Hot Off The Press Welcome back to you all and I hope you all had a delightful festive season. I have...
Professor Jean Bennett – Melbourne November 2024
It was great for Rosemary and I to meet up with Professor Jean Bennett...